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Abstract Ricin, cholera, and Shiga toxin belong to a family of
protein toxins that enter the cytosol to exert their action. Since
all three toxins are routed from the cell surface through the
Golgi apparatus and to the endoplasmic reticulum (ER) before
translocation to the cytosol, the toxins are used to study di¡er-
ent endocytic pathways as well as the retrograde transport to
the Golgi and the ER. The toxins can also be used as vectors to
carry other proteins into the cells. Studies with protein toxins
reveal that there are more pathways along the plasma mem-
brane to ER route than originally believed. # 2002 Published
by Elsevier Science B.V. on behalf of the Federation of Euro-
pean Biochemical Societies.
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1. Introduction
A large group of bacterial and plant toxins bind to cells by
one moiety whereas another moiety with enzymatic activity
enters the cytosol and exerts the action (for review, see [1^5]).
Most of these toxins have to be endocytosed before translo-
cation to the cytosol. Several bacterial toxins, such as diph-
theria toxin and anthrax toxin, enter the cytosol in response
to the low pH found in endosomes, whereas other toxins, such
as the plant toxin ricin, and the bacterial toxins cholera and
Shiga toxin (their structures are shown in Fig. 1) are trans-
ported not only to endosomes, but retrogradely through the
Golgi apparatus and to the endoplasmic reticulum (ER) be-
fore the enzymatically active part enters the cytosol (Fig. 2).
This complicated intracellular routing makes the toxins useful
as tools to study the pathways involved in this journey.
Several of the bacterial toxins are still a threat to human
health [1,2,6^9]. Knowledge about the action of toxins pro-
vides us with new possibilities to prevent and cure infectious
diseases. For instance, Shiga-like toxins secreted by Escheri-
chia coli seem to be an increasing problem even in developed
countries, and the toxin can cause renal failure and death,
especially among children [6,8]. Knowledge about the toxin
and its receptor has recently been used to create bacteria
with Shiga toxin receptor mimics [10] and to design soluble
molecules that might interfere with toxin binding [8,10], two
approaches that might be used in therapy.
The toxins are also used as components in targeted drug
treatment, for instance in cancer therapy. Since the toxins
block protein synthesis very e⁄ciently (about 2000 ribosomes
are destroyed per minute after entry of one ricin molecule),
directing toxins to cells for selective destruction is being tried,
and promising clinical trials are being performed [11,12]. Also,
a number of the protein toxins have been used as vectors to
bring into cells proteins or epitopes that are then presented at
the cell surface by MHC class I [13^17]. The toxins can there-
fore also be used for vaccination purposes.
In this article we will concentrate on the pathways used by
ricin, cholera and Shiga toxin to gain access to the cytosol,
and we will discuss the di¡erences and similarities between the
behavior of these toxins when exploiting the cell machinery on
their way into cells.
2. Endocytosis of ricin, cholera and Shiga toxin
The plant toxin ricin which binds to both glycoproteins and
glycolipids with terminal galactose and therefore binds all
over the cell surface can be used as a membrane marker
that is internalized by all endocytic mechanisms operating in
a given cell [3,5]. Thus, ricin has proven valuable to study
regulation of endocytic mechanisms. Di¡erent types of endo-
cytosis can operate simultaneously, and an overview of such
mechanisms is presented in Fig. 3. Several of the endocytic
mechanisms are susceptible to cholesterol depletion. Not only
do caveolae disappear upon removal of cholesterol from the
plasma membrane (or upon addition of cholesterol-binding
drugs such as ¢lipin) [18,19], but also uptake from clathrin-
coated pits [19^21] is inhibited after removal of cholesterol
with methyl-L-cyclodextrin. Only £at clathrin-coated mem-
brane areas can be visualized after such treatment. It is not
known whether cholesterol is required in the invaginated
clathrin-coated pit as a structural component, or whether it
could be involved in signalling necessary for formation of this
structure. Recent data reveal that even macropinocytosis is
critically dependent on membrane cholesterol. When the level
of cholesterol is reduced, membrane recruitment of activated
Rac, actin reorganization and ru¥ing do not occur [22].
In contrast to ricin, cholera toxin and Shiga toxin bind to a
de¢ned receptor structure. Cholera toxin is a pentavalent tox-
in (Fig. 1) that binds to the glycolipid GM1, before it is
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endocytosed [7]. The toxin can in many cell types be visualized
in caveolae, which have been suggested to be involved in
endocytosis of this toxin in di¡erent cell types. This may be
the case in some cells such as endothelial cells, where there is
evidence for a dynamin-dependent ¢ssion of caveolae [23,24].
However, cholera toxin is endocytosed also in cells without
caveolae [25,26], and recent data have revealed that a large
fraction of cholera toxin can be taken up by clathrin-depen-
dent as well as clathrin- and caveolae-independent endocytosis
in di¡erent cell types [25,27,28]. Actually, the toxin that is
visualized in caveolae could be retained in these structures
without being internalized, and this might be the reason for
the high concentration of toxin^receptor complexes in caveo-
lae. In fact, caveolae have in some cells been shown to be
quite stable structures that do not pinch o¡ unless they are
stimulated to do so [29]. It should be noted that although
cholera toxin binds GM1, the toxin can not automatically
be used to determine the normal distribution of this lipid.
The pentavalent binding, as well as the ability of the toxin
to cause signalling, might very well a¡ect the distribution of
the toxin^receptor complex. Toxin-induced relocalization of
GM1 has actually been demonstrated in di¡erent cell types
[30,31]. Thus, the fact that genestein, a tyrosine kinase inhib-
itor, inhibits internalization of the cholera toxin B-subunit [32]
does not necessarily mean that the endocytic mechanism used
by cholera B is a¡ected by genestein, it could also mean that
the movement of the toxin into a given pathway involves ki-
nase activity. In agreement with this idea is the ¢nding that
genestein inhibits uptake of cholera toxin in normal BHK
cells, but after expression of antisense to clathrin heavy chain
and complete inhibition of the clathrin-dependent pathway, it
does not longer inhibit [25]. One interpretation of this ¢nding
is that there is a requirement for tyrosine kinase activity in the
aggregation of cholera toxin into clathrin-coated pits, a pro-
cess that is currently not understood.
Shiga toxin which like cholera toxin has ¢ve subunits (B)
that bind to a glycolipid receptor, Gb3, is also endocytosed
from clathrin-coated pits, although in some cells other endo-
cytic mechanisms can be involved in endocytosis of the intact
toxin or its binding subunits [2,9,28,33]. It should be noted
that Shiga toxin can activate tyrosine kinases such as Lyn [34]
and Yes [35] in some cell types. However, the mechanism
behind the aggregation of Shiga toxin in clathrin-coated
pits, and the possible cell type-dependent di¡erences have
not yet been elucidated. The extent of localization of Shiga
toxin^receptor complexes to lipid rafts seems to be cell-depen-
dent [36], and could be one factor giving rise to di¡erences in
endocytosis and intracellular sorting of this toxin. Interest-
ingly, Shiga toxin and cholera toxin have been reported to
colocalize in the same lipid rafts [37], but it is not known
whether this is a general phenomenon and whether this re-
£ects the original localization of GM1 and Gb3 in these cells.
Thus, future studies designed to elucidate these mechanisms
will provide us with information about the toxins and their
exploitation of the cellular machinery, as well as about the
properties of glycolipids and their localization in rafts.
3. Transport of ricin, cholera and Shiga toxin from endosomes
to the Golgi apparatus
How do toxins move from endosomes to the Golgi appa-
ratus? Studies of intracellular transport have revealed that
there is more than one pathway leading from endosomes to
the Golgi apparatus [33,38^41]. One well characterized path-
way is the Rab9-dependent pathway from late endosomes to
the Golgi apparatus, a pathway that is involved in transport
Fig. 1. Structures of ricin (A), cholera toxin (B), and Shiga toxin (C). At the top are shown the crystallographic structures of ricin (PDB pro-
tein data bank: 2AA1), Shiga toxin (PDB protein data bank: 1DMO) and cholera toxin (1XTC). Below are shown the schematic structures:
ricin is not processed by the target cells ; cholera toxin A fragment is cleaved by the bacteria producing the toxin (arrow); Shiga toxin A frag-
ment is processed by the target cells (arrow). The enzyme that normally cleaves Shiga A is furin [45].
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of the mannose-6-phosphate receptors [42,43]. Also, transport
of furin, an enzyme responsible for the cleavage and activa-
tion of several protein toxins [44], including Shiga toxin [45],
seems to be transported from the cell surface through late
endosomes and to the Golgi apparatus [40]. However, trans-
port to the Golgi apparatus of ricin [33,41], Shiga toxin [33],
Shiga toxin B-subunit alone [38,46], as well as the Golgi
marker TGN38 [39,40] seems to occur from an earlier endo-
somal compartment. This has been shown partly by micros-
copy, and partly by selective inhibition of the Rab9-dependent
pathway by inducible synthesis of dominant negative mutants
of Rab9 that will inhibit transport of the mannose-6-phos-
phate receptors to the Golgi. Evidence for transport of ricin
from early endosomes to the Golgi and not from late endo-
somes by a Rab9-independent pathway was provided by ex-
periments demonstrating that ricin transport to the Golgi also
occurs independently of Rab7 [33]. When using microscopy to
investigate routing of toxins, it is important to be aware of the
fact that toxins can travel through a certain organelle without
being visible, possibly due to a high exit rate compared to the
entry rate into a given organelle. Another possibility is that
the number of toxin molecules per membrane area becomes
low due to a large membrane content of the organelle. For
instance, ricin is transported to the ER, but has never been
visualized by microscopy in this location.
How are toxins and other molecules transported from early
endosomes to the Golgi apparatus? There may be more than
one pathway: Shiga toxin B-chain transport has been reported
to be dependent on the small GTP-binding proteins Rab11
and Rab6aP [46], whereas ricin transport seems to occur inde-
pendently of Rab11 [41]. Perhaps ricin, due to its ability to
bind di¡erent types of molecules, can be transported by more
mechanisms than a toxin such as Shiga toxin. Also, cholera
toxin is transported rapidly to the Golgi [28,47], but again, the
pathway is not well characterized. It has been suggested that
this toxin can pass through endosomes that are di¡erent from
the ones that contain transferrin, but the authors also sug-
gested that the toxin might be rapidly sorted away from trans-
ferrin [28]. Detailed kinetic studies are required to determine
whether lack of colocalization could be due to retention of the
toxin in certain membrane domains or rapid segregation from
other markers. Although the organelles and the regulatory
mechanisms involved are not yet well characterized, di¡erent
factors important for toxin transport to the Golgi have been
found. The v/t-SNARE system seems to be involved both in
the transport of TGN38 and Shiga B [46]. In the case of Shiga
toxin, the lipid composition of the receptor seems to be im-
portant for transport of the toxin to the Golgi apparatus [2,9].
Also the cholesterol content of the cell may regulate the frac-
tion of di¡erent toxins such as ricin [33,48], cholera toxin [49]
and Shiga toxin B-subunit [36] transported in the direction of
the Golgi apparatus. Furthermore, signalling via protein ki-
nase A and Ca2þ/calmodulin is important for this transport of
ricin to the Golgi [3]. Studies of toxin transport to the Golgi
apparatus might provide us with knowledge about new path-
ways previously not characterized.
4. Retrograde toxin transport to the ER and translocation to
the cytosol of the enzymatically active part of the toxin
One well characterized retrograde transport system in the
Golgi apparatus involves the formation of COPI-coated
vesicles which are responsible for transport of proteins with
Fig. 2. The plant toxin ricin and the bacterial toxins cholera toxin
and Shiga toxin all bind to cells before they are endocytosed, trans-
ported retrogradely to the Golgi apparatus and the ER, and then
the enzymatically active subunit is translocated to the cytosol.
Fig. 3. Endocytic mechanisms operating in cells.
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the KDEL sequence, an ER retention signal [50,51]. This se-
quence becomes bound to so-called KDEL receptors which
are distributed throughout the entire Golgi apparatus [51].
Some protein toxins that contain a KDEL or a KDEL-like
signal such as Pseudomonas exotoxin A seem to be trans-
ported retrogradely by this mechanism since antibodies to
the KDEL receptor or saturation of KDEL receptors by over-
expression of lysosome-KDEL will protect cells against this
toxin [52]. Also mutations of the KDEL sequence inhibit tox-
icity [53]. Cholera toxin has a KDEL sequence in its A-sub-
unit, and mutations in this sequence cause a delay in the
action of the toxin, but not a complete inhibition of its action,
suggesting that retrograde transport can occur independently
of the KDEL receptor [54]. Furthermore, the cholera B-chain,
which lacks a KDEL sequence, can be seen in the various
Golgi cisterns, demonstrating retrograde transport which oc-
curs independently of the A-subunit [55]. Importantly, neither
Shiga toxin nor ricin has a KDEL sequence but are never-
theless transported from the Golgi apparatus to the ER before
translocation to the cytosol [3]. How does this occur? One
possibility would be that they are transported in COPI-coated
vesicles without being bound to the KDEL receptor. It has
been shown that even resident Golgi enzymes are transported
in these vesicles, a ¢nding in agreement with the maturation
model of the Golgi apparatus [56]. However, even when
COPI-dependent transport is inhibited by antibodies to
COPI, retrograde transport of Shiga toxin transport occurs
[57,58]. It was recently published that this retrograde trans-
port occurs by a Rab6-dependent pathway [57,58], which
might also be involved in retrograde ricin transport. However,
this has not yet been investigated.
After entry of the toxins to the ER, ER-resident chaperones
and enzymes can be involved in facilitating reduction of the
internal disul¢de bonds and preparation of the toxin A-sub-
unit for transport into the cytosol by the Sec61p complex.
This protein complex is normally involved in transport of
newly synthesized proteins from the cytosol into the ER,
but has also been shown to be required for transport of mis-
folded proteins (even with carbohydrates added) back to the
cytosol where they are then ubiquitinylated and degraded by
proteasomes [59^61]. In the case of cholera toxin it was dem-
onstrated that after arrival of the intact toxin to the ER, the
enzyme protein disul¢de isomerase is involved in the reduction
of the disul¢de bond of the A-subunit, thus releasing the
active A1 subunit, which can then be transported to the cy-
tosol [62]. It has however not been demonstrated whether the
intact A might be translocated to the cytosol and then re-
duced. The Sec61p complex seems to be involved in trans-
location of several toxins. Ricin A-chain [63], cholera toxin
[64] and Pseudomonas exotoxin A [65] can all be found asso-
ciated with this protein complex, and ricin A-chain transport
through the complex has been demonstrated [66]. The details
in the translocation process and the molecules involved in
reduction of the internal disul¢de bonds in ricin and Shiga
toxin have not yet been characterized. It has also been sug-
gested that even the binding subunits (the toxin B-chains)
might become translocated from the ER to the cytosol
[13,67]. However, this has not yet been directly demonstrated.
5. Conclusion
Protein toxins exploit intracellular transport to move all the
way from the cell surface to the ER before they are trans-
located to the cytosol where they exert their action. Knowl-
edge about the mechanisms involved in toxin transport and
membrane translocation can provide us with increased under-
standing of transport in general, and may improve our possi-
bilities to use the toxins in therapy, both for vaccination pur-
poses and in targeted cell elimination. Clearly more work is
needed to understand the action of these fascinating mole-
cules.
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